Member Info for Num4

Our Chairman just retweeted a tweet by Sierra for job opening in business developement. Interesting!
Sierra have already allocated the ~$20million in milestones due to the CPF partnership, imo just some paperwork and potenial on-license to get across the line before this is released but it all points towards Sierra making progress behind the scenes with SRA737.

You've basically got a limited amount of time now to build a holding, this won't go like other rises in pharma stocks in my opinion. It could be the end of Sareum and if your not in your out. They have nothing else in the pipeline after tyk2s, they've mentioned about going shopping after a deal but I can't see it.

Parker is clear with his take on it.."the Directors will continue to review the potential higher value of a later-stage licensing deal versus the requirement for any additional funding."

Additional funding looking highly unlikely, licensor will know that. You'd want to be in before the COVID Grant or they will pay more again.

That's why we are all here and this could come anytime, volume yesterday suggests this could be close, patent would have been the stumbling block, now overcome.
Huge deal in the pipeline for Sareum.

Yes Zylo, it's very difficult to find a negative at the minute, the talk of any placing is rubbish, only negative would be if we deal with another non major pharma for our tyk2s but I don't feel that will be the case.

Hey Thoth,
Like old days the board is more sensible on a night but I am watching.
The huge gains from other stocks will also help Sareums movement towards a sensible price. I feel we will get an RNS in the morning, only because it's my birthday and Tim has previously given crap presents for the last 10years. Haha.
I said it previously and I still stand by in, I think Tim and John will start on a specific covid compound after they see some data from what their SDC1801 does. All fully funded of course. They're last hurrah

Normally Sareum would use innovate UK for funding and on a new target they would apply for a feasibility study grant, this previously cost £200k for tyk2 against T-ALL, grant would be £140k.

Time has been of benefit for Sareum in the fact that they have watched others and now it looks like enough data is available for a JAK to treat COVID.

The volumes today and the after hours buys would suggest the grant is close, for the grant to be awarded the applicant must be able to show they can commence within 4 weeks (usually), grants can also have partners - big pharma partners.
For Sareum to get off the line with COVID they need the grant to be partnered with a pharma who has the capacity to get this into patients. I'm sure they have plenty of takers as they have been in discussion for a while with potential partners.
Lastly if your going into partnership for the grant you can be sure a seperate commercial license will be negotiated at the same time.
80% costs paid to prove efficacy and a potential treatment which gets the world out of lockdown, then there is the real targets of SDC1801.

Hold on to some shares as long as you can. Best of luck for the forthcoming days and weeks.

Let's not forget Sareums, now proven, highly valuable core skill is in small molecule design. Tim and John have talents which go beyond the normal R&D teams, hence why they started their own company.
For the right situation, COVID, they may well be tasked with producing a small molecule for more effective targeted treatment of COVID. They have the effective building blocks with SDC1801 to take this back to the design, under funding from a major to produce a more targeted compound on the fly, as new scientific data emerges. It is the perfect solution for Tim and John to continue doing what they do best, an unlimited budget and time to work as we continue to learn about the virus. Treatment not cure, incase a cure never comes.

Should focus the pharma minds in treatment using a non black box molecule, baricitinib doesn't play nice with corticosteroids, Sareums inability to make MTD and this further research of Jak compounds having a positive effect almost guarantees the grant.
We need to get this ball rolling now so it can slowly start steamrolling the other Jak's in COVID and beyond.

Sareum have told us about this early, all other announcements are when it is granted. Probably because we will find it if they don't release it. They are learning well.

https://www.medpagetoday.com/reading-room/aad/psoriasis/88067

Hey RMM,
Excellent post! I agree that taking the SDCs into trials is unlikely but that is only because of the potential and the on-trend molecules they are, they do state the strategy is up to early clinical stages and this would be a first for a 100% owned compound - I'd assume ICR done most of the work to get Chk1 into trials.
The good thing is it is not outwith our strategy or expertise looking at the NEDs for guidance here - so the ultimatum to the interested parties is that we are full steam ahead into trials with SDCs unless you want it now for $$$$$$$$$$$$.
Tim still hasn't altered the timetable for trials so just over 3 month maximum.

Some great additions to this board! Not had time to research lately but it's in good hands, as is Sareum and our money. Enjoying some Cyprus sun for the next few days. Have a good weekend all and here's to breaking 1p today, cheers.

As far as tyk2/jak1 goes, it must be the hottest target in immunology, when you consider how confident BMS are and then the current pipeline at Pfizer:https://pfe-pfizercom-d8-prod.s3.amazonaws.com/product-pipeline/Pipeline_Update_28JUL2020_2.pdf?g2LC1wfK6cIkN8rsfuhmcxWroOniJD0I

It's not hard to conclude that Tim and John certainly picked the right target all those years ago during development. Pfizer are throwing money at plenty autoimmune diseases in every phase, when you consider the money involved here a competitive compound with a potentially cleaner safety profile would be a disaster for Pfizer, you would really think they would hedge their bet and in doing so take an interest in Sareum's compounds.
Surely that's just good business practice when you have a £billion+ pound bet on, hopefully they've got some competition in securing the asset, once we get pre-clinical package complete it may come very quickly if not on the same announcement.
Never a better time to be an investor.

It's about £4million, certainly secures the company. Our Institution must have joined these dots previously.

From my understanding, this is the SEC approving the terms of the S-3 they filed on the 6th August, the S-3 is obviously the $150million, as part of that they have a sales agreement for $20million already planned which dilutes the share price - that's why they have dropped today as the execute price will be around the $11.75 mark.
The $20millon, by coincidence, or not, is the cost of milestones they are due for SRA737.

So upcoming from Sierra imo is a share sale by jeffries amounting to approx $20million, the share price has already factored this in after the 11:11 announcement today - so onwards and upwards for them and if all signs are reading correct the milestone should be in the post.

I've already asked the following questions using the new investor meet company forum:
Question 1:
Can you explain in further detail the differentiation of SDC-1801 with SDC-1801, you are stating they are both TYK2/JAK1 inhibitors but when studying the patent document for kinase selectivity, filed March 13, 2019 it appears SDC-1802 is more selective to TYK2/JAK2.
Question 2:
What publication will the upcoming SDC-1801 data be featured in? Do you have a date for this?
Question 3:

We have identified an institutional investor being declared yet the company has not responded to this fact. Can you confirm you have successfully onboarded an institution and at what levels of ownership are they anticipating.
Question 4:
Are you packaging the JAK assets SDC-1801 & SDC-1802 together for a license or separate?
Question 5:
How confident are you in achieving MTD for SDC-1801 and do we have the same problem for SDC-1802? Can we move into PI without MTD and indication dependant, achieve it during PI, in compliance with all ethical regulations?
Question 6:
Has the pending COVID-19 grant presented an opportunity to delay any pre-clinical license deal due to grant funding in progressing PI for what would have previously been the licensor's costs?
Question 7:
Sareum currently has nothing in the pipeline behind SDC-1801/SDC-1802, are you planning on bringing some compounds back into development as Sareums extremely talented skillset and core skills on molecule design are now not getting utilized. What's the forward-looking plan for Sareum over the next 3-5years?
Question 8:
You have mentioned that efficacy against human skin samples forms part of the pre-clinical package for SDC-1801, why has this data not been released yet?
Question 9:
Can you expand on the grant application, how much is it for, what are the primary objectives of the grant?
Question 10:
Was the Aurora+FLT3 license COVID therapy related?

Not able to stream live due to present location but will be listening in via phone, hopefully.

States 30th June yet volume on that day doesn't match. Did Mr. Parker sneak another 2million from under our noses, or was it Mrs. Parker...

30-Jun-20 Buy Stephen Parker 0.60 GBX 2,160,686 3,906,663
30-Jun-20 Buy Clive Birch 0.60 GBX 751,394 2,001,394
30-Jun-20 Buy Michael Owen 0.60 GBX 548,846 548,846
30-Jun-20 Buy John C Reader 0.60 GBX 5,100,880 48,548,462
30-Jun-20 Buy Timothy J Mitchell 0.60 GBX 5,118,679 47,399,150
30-Jun-20 Buy Stephen Parker 0.60 GBX 2,000,000 3,906,663

Yes Andy - time is certainly of the essence and just a few quotes from Livermore to appreciate this wait:
"When a man is right, he wants to get all that is coming to him for being right."
"It never was my thinking that made the big money for me, it always was my sitting."

Pharma is certainly in a bull market and we are right on the money with our holding of Sareum at these levels.

GLA

Yes, Loopylo - this has been posted, probably on the 24th July, if you didn't know we are ahead of the BOD on here for Sareum news. Keep looking though and posting as it all helps for new viewers.